Sumit Chanda, Ph.D.
Research Assistant Professor(s)
Lab Website
Sumit Chanda's Research Focus
Sumit Chanda's Research Report
We are studying cellular proteins required for both influenza A and retrovirus/HIV infection. Also, we are investigating novel molecules that regulate or respond to Pattern Recognition Receptor (PRR) signaling. Taken together, we aim to elucidate the repertoire of host proteins required for viral infection, and understand the molecular strategies adapted by these viruses as countermeasures to innate immune responses.
To understand these events on a global level, our lab uses a series of systems-level approaches, including genome-wide RNAi, proteomics and protein-protein interaction (PPI) analysis, and high content imaging. These, and other, tools are helping us to build a comprehensive cellular "roadmap" exploited by these viruses to enable their propagation within a cell. These studies are expected to provide unprecedented insight into the molecular circuitry commandeered by these pathogens to establish infection, and will offer new opportunities for the development of "next generation" host factor and immune-mediated antivirals.
Sumit Chanda's Bio
Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda also holds an Adjunct Professor appointment at the Salk Institute for Biological Studies, as well as a Visiting Scientist position at the Genomics Institute of the Novartis Research Foundation.
Other Appointments
Adjunct Professor, Salk Institute for Biological Sciences
Visiting Scientist, The Genomics Institute of the Novartis Research Foundation
Visiting Scientist, The Scripps Research Institute
Publications
NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses.
Guo H, König R, Deng M, Riess M, Mo J, Zhang L, Petrucelli A, Yoh SM, Barefoot B, Samo M, Sempowski GD, Zhang A, Colberg-Poley AM, Feng H, Lemon SM, Liu Y, Zhang Y, Wen H, Zhang Z, Damania B, Tsao LC, Wang Q, Su L, Duncan JA, Chanda SK, Ting JP
Cell Host Microbe 2016 Apr 13 ;19(4):515-528
A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals.
Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S, Pache L, De Jesus PP, Hull MV, Chang M, Chan JF, Cao J, Poon VK, Herbert K, Nguyen TT, Pu Y, Nguyen C, Rubanov A, Martinez-Sobrido L, Liu WC, Miorin L, White KM, Johnson JR, Benner C, Sun R, Schultz PG, Su A, Garcia-Sastre A, Chatterjee AK, Yuen KY, Chanda SK
bioRxiv 2020 Apr 17 ;
Sensor Sensibility-HIV-1 and the Innate Immune Response.
Yin X, Langer S, Zhang Z, Herbert KM, Yoh S, König R, Chanda SK
Cells 2020 Jan 20 ;9(1)
Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K, Martin-Sancho L, Pal LR, Pu Y, Riva L, Yin X, Sinha S, Nair NU, Chanda SK, Ruppin E
Mol Syst Biol 2021 Nov ;17(11):e10260
Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy.
Martin-Sancho L, Tripathi S, Rodriguez-Frandsen A, Pache L, Sanchez-Aparicio M, McGregor MJ, Haas KM, Swaney DL, Nguyen TT, Mamede JI, Churas C, Pratt D, Rosenthal SB, Riva L, Nguyen C, Beltran-Raygoza N, Soonthornvacharin S, Wang G, Jimenez-Morales D, De Jesus PD, Moulton HM, Stein DA, Chang MW, Benner C, Ideker T, Albrecht RA, Hultquist JF, Krogan NJ, García-Sastre A, Chanda SK
Nat Microbiol 2021 Oct ;6(10):1319-1333
The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment.
Riva L, Goellner S, Biering SB, Huang CT, Rubanov AN, Haselmann U, Warnes CM, De Jesus PD, Martin-Sancho L, Terskikh AV, Harris E, Pinkerton AB, Bartenschlager R, Chanda SK
J Virol 2021 Oct 27 ;95(22):e0099621
Functional landscape of SARS-CoV-2 cellular restriction.
Martin-Sancho L, Lewinski MK, Pache L, Stoneham CA, Yin X, Becker ME, Pratt D, Churas C, Rosenthal SB, Liu S, Weston S, De Jesus PD, O'Neill AM, Gounder AP, Nguyen C, Pu Y, Curry HM, Oom AL, Miorin L, Rodriguez-Frandsen A, Zheng F, Wu C, Xiong Y, Urbanowski M, Shaw ML, Chang MW, Benner C, Hope TJ, Frieman MB, García-Sastre A, Ideker T, Hultquist JF, Guatelli J, Chanda SK
Mol Cell 2021 Jun 17 ;81(12):2656-2668.e8
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
Ho JSY, Mok BW, Campisi L, Jordan T, Yildiz S, Parameswaran S, Wayman JA, Gaudreault NN, Meekins DA, Indran SV, Morozov I, Trujillo JD, Fstkchyan YS, Rathnasinghe R, Zhu Z, Zheng S, Zhao N, White K, Ray-Jones H, Malysheva V, Thiecke MJ, Lau SY, Liu H, Zhang AJ, Lee AC, Liu WC, Jangra S, Escalera A, Aydillo T, Melo BS, Guccione E, Sebra R, Shum E, Bakker J, Kaufman DA, Moreira AL, Carossino M, Balasuriya UBR, Byun M, Albrecht RA, Schotsaert M, Garcia-Sastre A, Chanda SK, Miraldi ER, Jeyasekharan AD, TenOever BR, Spivakov M, Weirauch MT, Heinz S, Chen H, Benner C, Richt JA, Marazzi I
Cell 2021 May 13 ;184(10):2618-2632.e17
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, Pache L, Chan CC, Lai PM, Chan CC, Poon VK, Lee AC, Matsunaga N, Pu Y, Yuen CK, Cao J, Liang R, Tang K, Sheng L, Du Y, Xu W, Lau CY, Sit KY, Au WK, Wang R, Zhang YY, Tang YD, Clausen TM, Pihl J, Oh J, Sze KH, Zhang AJ, Chu H, Kok KH, Wang D, Cai XH, Esko JD, Hung IF, Li RA, Chen H, Sun H, Jin DY, Sun R, Chanda SK, Yuen KY
Nature 2021 May ;593(7859):418-423